All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know GvHD.

  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The GVHD Hub is an independent medical education platform, sponsored by Medac and supported through independent educational grants from Incyte, Sanofi and Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

#ASCO22

Share:

Jul 1, 2022


X post image

7 Jun 2022

We hope you enjoyed following our live updates and congress coverage! 🎓

#ASCO22 was covered by us in Chicago, IL, as well as virtually!

Keep an eye on our socials for post-congress key points and insights! 📲

#medicalcongress #cancerawareness
X post image

4 Jun 2022

CONGRESS #ASCO22 | Cole Harris Sterling @hopkinskimmel talks about PTCy for #GvHD prophylaxis in PTCL. N=65. 45% had GvHD, 2 were grade 3-4 aGVHD & 3 were severe cGVHD. In univariate analysis only PB/400 cGy TBI was a significant predictor of survival, relapse or NRM. #bmtsm
X post image

4 Jun 2022

CONGRESS #ASCO22 | Sara Sakowitz @dgsomucla reports on the association of frailty with outcomes of allo-HSCT. Patients were split into frail or not using a binary indicator. Frail HSCT pts showed an increase in-hospital mortality, complications & overall resource use #GvHD #bmtsm
X post image

4 Jun 2022

CONGRESS #ASCO22 | @vickysimpleton @CIBMTR @MedicalCollege describes including pt reported outcomes into a HSCT survival calculator. N=1033. Although adding PRO to the calculator did not improve its performance, pre-HSCT PRO scores significantly correlated with OS #GvHD #bmtsm
X post image

4 Jun 2022

The GvHD Hub will be covering the following session today virtually:

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Stay tuned for live updates, key insights, and interview coverage!

#ASCO22 #medicalcongress #cancerawareness
X post image

31 May 2022

The @gvhd_hub will be covering the 2022 ASCO Annual Meeting!

Date: 3–7 June
Location: Hybrid

Keep an eye on our socials for live coverage throughout the day from our virtual and in-person attendance in Chicago, IL! 🗣💻

#ASCO22 #medicalcongress #cancerawareness

<span>&nbsp;</span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content